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CHAPTER 16 
Atrial Natriuretic Peptide in Normal 
Humans: Hemodynamic and Renal Effects 
after Single and Repeated Bolus Injection 
*Gert Müller-Esch, * Jürgen Potratz, ^Michael Kentsch, 
**Peter Ball, tRupert Gerzer, *Sabine Klohs, 
* Rüdiger Lawrenz, and * Peter C. Scriba 
Departments of * M e d i c i n e and **Biochemical Endocrinology, M e d i c a l University 
Lübeck, and tDepartment of M e d i c i n e , University München, 
F e d e r a l Republic o f Germany 
To study cardiovascular and diuretic effects and to establish whether there 
is an attenuation of response after repeated application, we gave a single or 
two 30-min-apart bolus injections of 200 |xg human atrial natriuretic peptide 
(a-hANP). Before and after a - h A N P bolus injections, echocardiography was 
performed and plasma atrial natriuretic peptide (ANP) and cyclic guanosine 
monophosphate (cGMP) as well as urinary c G M P excretion were deter-
mined. Plasma c G M P rose from basal 3.4 ± 1.1 to 25.0 ± 6.7 nmol/liter 
within 10 min after the first injection and from 20.0 ± 6.0 before the second 
administration to 32.7 ± 11.1 nmol/liter another 10 min later. Urine volume 
(30-min sampling periods) increased from 2.1 ± 2.5 to 16.1 ± 5.3 after the 
first and to 22.6 ± 7.0 ml/min after the second bolus. Urine sodium excre-
tion increased from 6.2 ± 2.9 to 43.0 ± 18.5 and 38.7 ± 21.0 mmol/hr. After 
each a - h A N P bolus, there was a significant decrease in mean arterial blood 
pressure and increase in heart rate. The ejection fraction increased from 66.2 
± 3.7 to 76.4 ± 4.0% after the first bolus and from 66.8 ± 3.8 before the 
second to 76.9 ± 5.0 after the second a - h A N P bolus. A l l reported changes 
are significant (/? < 0.01). 
Single and repeated bolus applications of 200 |mg of a - h A N P in healthy 
volunteers increases plasma and urinary c G M P , diuresis, and natriuresis as 
well as echocardiographically determined ejection fraction and decreases ar-
terial blood pressure. Reproducible diuretic effects and improved cardiac 
Performance after repeated bolus application of a - h A N P may be beneficial 
in the treatment of congestive heart failure. 
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a - h A N P is a cardiac hormone with diuretic, natriuretic, and vasodilating 
properties (1-3). When given either as a bolus or as an infusion intravenously 
in normal humans, a - h A N P causes a rise in urinary volume and sodium 
excretion (1,2). The hemodynamic actions of a - h A N P are yet not well de-
fined. After an a - h A N P bolus, Richards et al. observed an increase of heart 
rate and adecrease of blood pressure (1). During infusion of a - h A N P , Cuneo 
et al. could not detect changes of heart rate or blood pressure (4), but Indolfi 
et al. reported decreased blood pressure while the heart rate was kept con-
stant by cardiac pacing (5). Vasodilating actions (4) as well as other hemo-
dynamic and diuretic effects of a - h A N P depend on the application scheme 
and the given dose (6). 
In this study, our aim was to investigate the effects of Single and repeated 
high dose a - h A N P bolus injections in normal humans on (a) c G M P response, 
(b) hemodynamic parameters detectable by echocardiography, and (c) di-
uresis and natriuresis. 
MATERIALS AND METHODS 
The first part of the study (protocol 1) was performed in seven healthy 
volunteers (six men and one woman; 27.7 ± 1.8 years) without any evidence 
of heart disease. After an overnight fast and bed rest, 200 |xg of a - h A N P 
(Bissendorf Peptide, Wedemark, FRG) were given as a bolus injection 
intravenously. 
Heart rate and blood pressure were monitored noninvasively by an auto-
matic device (DynamapR). M-mode echocardiography was performed 40 and 
20 min before as well as 5, 10, 15, 30, 45, 60, 120, and 180 min after the 
injection of a -hANP. 
Venous blood samples were drawn for the determination of A N P , c G M P , 
hematocrit, sodium, potassium, and serum osmolality at - 2 0 , ± 0 , +2, +5, 
+ 10, +20, +35, +60, +90, and + 180 min. Urine was collected at 30-min-
ute intervals for measuring the excretion of sodium, potassium, and c G M P . 
Urine Output was replaced throughout the study by oral water. 
Informed consent was given; the study was approved by a local ethics 
committee. 
Echocardiography 
A n I R E X III (m-mode) echocardiograph together with a C A R D I O 200 
Computer for the elaboration of the data was used. The left ventricular di-
mensions were obtained when the ultrasonic beam was directed at the Cham-
ber between the mitral valve echos and the papillary muscle echos (7). The 
end-diastolic diameter (EDD) was taken at the peak of the R-wave and from 
the trailing edge of the left side of the intraventricular septum to the leading 
edge of the posterior endocardial echo. The end-systolic diameter (ESD) 
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was taken at the peak downward motion of the intraventricular septum. Ven-
tricular volumes—end-diastolic volume (EDV) and end-systolic volume 
(ESV) , stroke volume (SV), and cardiac index (CI)—were obtained utilizing 
the formula of Teicholz et al. (8). The ejection fraction (EF) was calculated 
according to the method of Quinones et al. (9). 
A N P (without prior extraction; I B L , Hamburg, F R G ) a n d cGMP(10) were 
measured by radioimmunoassay. 
Data are given as means ± Standard deviation (SD). For Statistical anal-
ysis, Studenfs Mest for paired data and the analysis of variance for repeated 
measures over time (11) were used. 
In the second part of the study (protocol 2), 200 jxg of a - h A N P were given 
twice as intravenous boluses at a 30-minute interval in six healthy volunteers 
(five men, one woman; 27.5 ± 2.4 years). Again, echocardiography was 
performed 40 and 20 min before the first administration as well as 5, 10, 15, 
and 30 min after each bolus and finally at 90, 120, and 180 min. As before, 
venous blood samples were drawn ( - 4 0 , - 2 0 , ± 0 , +2, +5, +10, +20, 
+ 32, +35, +40, +50, +60, +90, + 120, +150, + 180 min) and urine was 
collected at 30-minute intervals. 
Within 2 min after each injection, a transient heart rate increase together 
with a fall of mean arterial pressure occurred (Tables 1 and 2). These 
TABLE 1. Hemodynamic, echocardiographic, and laboratory findings after a 
Single bolus injection of <x-hANPa 
Analytical Methods 
Calculation and Statistics 
RESULTS 
Basal Max/min Time (min) 
Heart rate (min ') 
Mean arterial pressure (mm Hg) 
Stroke volume (ml) 
Cardiac index (liters/min/m 2) 
Urinary cGMP (nmol/min) 
Hematocrit (%) 
58.6 ± 4.67 
91.3 ± 5.7 
77.5 ± 15.1 
2.44 ± 0.41 
0.71 ± 0.25 
41.7 ± 3.3 
79.1 ± 7.4 
81.7 ± 6.4 
90.3 ± 10.2 
2.88 ± 0.41 
5.56 ± 1.94 
44.8 ± 3.2 
+ 4 
+ 2 
+ 10 
+ 10 
+ 35 
0 -30 
a Time: time of maximal deviation from baseline values. The significance of all differences 
between basal and maximal or minimal values (max/min): p < 0.01. 
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TABLE 2. Hemodynamic, echocardiographic, and laboratory Undings after 
repeated bolus injections of a-hANPa 
Basal Max/min Time (min) 
Heart rate ( m i n - 1 ) A65 .5 ± 8.6 79.5 ± 6.4 + 3 
B 60.2 ± 7.9 83.3 + 6.7 + 3 
Mean arterial pressure (mm Hg) A 9 0 . 0 3.9 82.5 6.4 + 4 
B 8 9 . 8 5.8 81.2 ± 5.3 + 2 
Stroke volume (ml) A83 .4 11.0 95.8 13.0 + 10 
B 7 8 . 6 13.1 90.2 ± 23.7 + 15 
Cardiac index (liters/min/m 2) A 2 . 9 7 ± 0.51 3.20 0.67 + 10 
B 2.63 0.46 3.28 ± 0.93 + 15 
Urinary cGMP (nmol/min) 0.62 0.42 5.68 1.75 30-
Hematocrit (%) 42.5 + 2.5 46.7 ± 2.3 + 40 
8 A: first a-hANP bolus; B: second a-hANP bolus. Time: t ime of maximal deviation from 
baseline values. The significance of all differences between basal and maximal or minimal 
values (max/min): p < 0.01. 
changes had disappeared another 5 min later. A l l subjects experienced mild 
to moderate facial flushing; no severe side effects were observed. 
Hemodynamic Findings 
In general, echocardiographic changes were most pronounced 10 to 15 min 
after the injection of a - h A N P and reached baseline values another 15 to 20 
min later. 
S i n g l e B o l u s ( P r o t o c o l 1) 
The results are given in Figs. 1 and 2 and in Table 1. E S D decreased mark-
edly. As E D D (basal, 5.06 ± 0.37 cm) remained constant, this resulted in an 
increase of the calculated EF . Correspondingly, S V and CI were augmented 
by about 17%. 
Repeated B o l u s I n j e c t i o n ( P r o t o c o l 2 ) 
Figures 3 and 4 and Table 2 give the results. Again, E S D decreased sig-
nificantly while E D D remained unchanged, leading to an increase of calcu-
lated E F , SV, and C I . Two-way analysis of variance did not disclose differ-
ences between the effects of a Single A N P bolus (protocol 1) and the first of 
two bolus injections (protocol 2). Repeated injection after 30 min provoked 
comparable hemodynamic responses; an attenuation or waning effect could 
not be demonstrated. 
3.5 
3.4 
3.3 H 
3.2 
3.1 
3.0 -I 
2.9 
2.8-
2.7-
2.6-
ESD 
[cm] 
-40 -20 »051015 30 45 60 90 180 
FIG. 1 . End-systolic diameter (ESD) after a Single bolus injection of 200 |xg of a-hANP in 
volunteers; 'p < 0.01. 
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ro/.i 
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FIG. 2. Ejection fraction (EF) after Single bolus injection of 200 p.g of a-hANP in volunteers; 
*p < 0 .01 . 
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FIG. 3. End-systolic diameter (ESD) and end-diastolic diameter (EDD) after repeated 
bolus injections of 200 \x,g of a-hANP at a 30-min interval; *p < 0.01. 
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FIG. 4. Ejection fraction (EF) after repeated bolus injections of 200 p,g of a-hANP at a 30-
minute interval; *p < 0.01. 
Renal Findings 
Single Bolus 
Within the first 30 min after injection, urinary volume increased ninefold 
and sodium excretion increased fivefold (Fig. 5), whereas potassium excre-
tion only doubled. Enhanced diuresis and natriuresis were still present at 
least 60 min later. 
Repeated Bolus Injections 
Again, the first injection of 200 \xg of a - h A N P produced clear-cut diuresis 
and natriuresis together with a moderate increase of potassium excretion. 
These effects were not different from those in protocol 1. Repeated injection 
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FIG. 5. Urinary volume (U) and urinary sodium excretion ( N a + ) after a Single bolus injec-
tion of 200 jxg of a-hANP in volunteers; *p < 0.01. 
of a - h A N P evoked prolonged renal actions when compared to Single bolus 
application (Fig. 6; Table 2). 
cGMP 
There was a marked rise of plasma c G M P in protocol 1, maximal values 
being observed between 10 and 20 minutes after injection (Fig. 7). Corre-
spondingly, urinary c G M P excretion increased nearly eightfold during the 
second collection period (0 to 30 min) (Table 1). 
The second a - h A N P bolus resulted in a further increase of plasma c G M P 
(Fig. 8) together with a more pronounced and persisting c G M P excretion up 
to the third collection period (30 to 60 minutes) (Table 2). During protocol 
2, urinary excretion rose from a basal value of 0.62 ± 0.42 to 4.70 ± 1.99 
mmol/min after the first bolus and to 5.68 ± 1.75 mmol/min after the second 
bolus. 
Other Findings 
A N P (basal value, 195 ± 94 pg/ml) rose nearly 15-fold after each injection 
and had nearly normalized 30 min later. After a Single bolus injection, the 
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FIG. 6. Urinary volume and urinary sodium and potassium excretion after repeated bolus 
injections of 200 |xg of a-hANP at a 30-min interval; *p < 0 .01. 
venous hematocrit had risen after half an hour by 7% and not yet returned 
to a basal value by the end of the study. Repeated injection produced a 
slightly greater rise of 10% (Tables 1 and 2). Serum concentrations of sodium 
and potassium remained unchanged during both protocols. Apart from a 
moderate, symptomatic flush, no side effects were observed in the healthy 
volunteers. 
DISCUSSION 
The data demonstrate reproducible transient increases of heart rate and a 
reduction of blood pressure after single and repeated bolus injections of 200 
|xg of a -hANP. These results correspond well with previous observations 
after a single bolus of 100 |xg of a - h A N P (1). 
Intravenous A N P in humans produces an increase of plasma c G M P and 
of urinary c G M P excretion (10). Probably because of the higher a - h A N P 
bolus dose of 200 jxg in the present study, the plasma and urinary response 
was more pronounced than previously reported after a bolus of 50 |xg (10). 
Cycl ic G M P seems to be not only a marker but also a mediator of A N P 
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FIG. 7. Serum cyclic guanosine monophosphate (C GMP) after a Single bolus injection of 
200 ixg of a-hANP in volunteers; *p < 0 .01. 
activity in vascular smooth muscle cells and endothelial cells (12). In v i t r o 
the Stimulation of c G M P production by A N P seems to be relatively irrever-
sible and the responsiveness to A N P is downregulated by prior exposure to 
A N P (12). Interestingly, we could not demonstrate any attenuation of plasma 
c G M P or urinary c G M P excretion after the second of two consecutive a-
h A N P bolus injections. After the second bolus, plasma c G M P rose from a 
still elevated level to an even higher peak concentration (Fig. 8). Corre-
spondingly, urinary c G M P excretion was also higher after the second than 
after the first a - h A N P bolus. Thus, there seems to be no evidence of a di-
minished c G M P response after high dose a - h A N P bolus applications at a 30-
min interval. 
Echocardiography after a - h A N P application revealed significant de-
creases of E S D which, with E D D remaining unchanged, led to an increase 
of computed E F after each a - h A N P injection. Also , S V and CI increased 
after a - h A N P . Similar to the c G M P response, there was no diminution of 
the echocardiographic effects of the second of two consecutive bolus injec-
tions in protocol 2. 
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FIG. 8. Serum cyclic guanosine monophosphate (cGMP) after repeated bolus injections of 
200 |xg of a-hANP at a 30-min interval; *p < 0.01. 
In healthy volunteers, there seems to be no evidence for a cardiodepres-
sive effect of the drug, which had been reported earlier in animals (13). In-
stead, the data point toward improved cardiac Performance which may, be-
cause of reported vasodilating effects of a - h A N P (3), be due to reductions 
of preload and afterload. Apart from possible direct myocardial effects, tem-
porarily elevated catecholamine levels as a consequence of vasodilatation 
(14) may contribute to improvement of cardiac Performance. 
L ike others (1,2,4,10), we observed increased diuresis and natriuresis af-
ter a - h A N P application in non-salt restricted healthy volunteers. Increases 
of diuresis and natriuresis in this study were larger than those previously 
reported after bolus injections, probably because of the higher dose of a-
h A N P (1,2,4,10). The recorded renal effects of a - h A N P persisted up to 60 
min after a bolus injection, which is remarkably longer than the duration of 
the cardiovascular effects. 
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Because of the prolonged renal action of a single dose, the second bolus 
in protocol 2 was given with an overlap of the renal effect of the first bolus. 
Nevertheless, there was no attenuation of diuretic and natriuretic effects 
after the second bolus. 
Endogenous plasma a - h A N P is elevated in patients with congestive heart 
failure and may have regulatory functions (15,16). Studies in small numbers 
of patients with congestive heart failure showed beneficial effects of a - h A N P 
due to its vasodilating and diuretic properties. Responses to a - h A N P in 
those patients has been varying. Although Riegger et al. (17) and Saito et al . 
(18) observed vasodilatory as well as diuretic effects after bolus injections, 
Firth (19) found only renal but no cardiovascular effects. After continuous 
infusion of a - h A N P in patients with heart failure, Mol l ina et al . (20) ob-
served beneficial effects in cardiovascular and renal parameters, but several 
others (21-23) could not confirm diuretic effects after a - h A N P infusion. 
In the present study, reproducible improvement of cardiac Performance 
and prolonged diuretic effects could be demonstrated in healthy volunteers 
after single and two consecutive bolus injections of 200 jxg of a - h A N P . A l -
though conclusions from data obtained in healthy volunteers must be drawn 
with care, one can speculate that improved cardiac Performance together 
with sustained diuresis and natriuresis after repeated high dose bolus appli-
cation of a - h A N P might be beneficial in the acute treatment of congestive 
heart failure. 
CONCLUSIONS 
Single and repeated bolus applications of 200 jxg of a - h A N P in healthy 
volunteers produces increases of plasma c G M P concentrations and urinary 
c G M P excretion, diuresis and natriuresis, heart rate and echocardiographi-
cally determined ejection fraction, and decreases in arterial blood pressure. 
Comparing the effects of two consecutive bolus injections of a - h A N P at a 
30-minute interval, there was no evidence for attenuation of c G M P re-
sponse, diuresis, natriuresis, or cardiovascular effects. 
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